Santen Pharmaceutical Co., Ltd. (TYO:4536)

Market Cap	518.43B
Revenue (ttm)	291.48B
Net Income (ttm)	31.42B
Shares Out	321.61M
EPS (ttm)	92.73
PE Ratio	17.38
Forward PE	14.95
Dividend	38.00 (2.36%)
Ex-Dividend Date	Mar 30, 2026

Volume	998,300
Average Volume	1,089,620
Open	1,598.00
Previous Close	1,580.50
Day's Range	1,583.50 - 1,612.00
52-Week Range	1,310.50 - 1,795.00
Beta	0.26
RSI	63.19
Earnings Date	Nov 6, 2025

About Santen Pharmaceutical

Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2α derivative and a beta-adrenergic receptor blocker for the treatment of glaucoma and ocular hypertension; ciclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis, as well as latanoprost, an ophthalmic emulsion of a prostaglan...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1890
• Employees: 3,849
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4536

Financial Performance

In 2024, Santen Pharmaceutical's revenue was 300.00 billion, a decrease of -0.65% compared to the previous year's 301.97 billion. Earnings were 36.25 billion, an increase of 36.09%.